Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center

Objectives: Mutation analysis by massive parallel sequencing (MPS) is routinely performed in the clinical management of lung cancer in Sweden. We describe the clinical and mutational profiles of lung cancer patients subjected to the first 1.5 years of treatment predictive MPS testing in an autonomous regional health care region... Conclusion: Although the increasing importance of MPS as a predictor of response to targeted therapies is indisputable, its role in prognostics or as a predictor of clinical course in nontargetable advanced stage lung cancer requires further investigation. READ ARTICLE

JTO Clinical and Research Reports DOI:10.1016/j.jtocrr.2020.100013

Authors: Sofi Isaksson, Bassam Hazem, Mats Jönsson, Christel Reuterswärd, Anna Karlsson, Håkan Griph, Jens Engleson, Gudrun Oskarsdottir, Ronny Öhman, Karolina, Holm, Frida Rosengren, Karin Annersten, Göran Jönsson, Åke Borg, Anders Edsjö, Per Levéen, Hans Brunnström, Kajsa Ericson Lindquist, …Maria Planck

Real-World OutcomesKirk SmithMarch 1, 2020Lung cancer, Massive parallel sequencing, Driver oncogenes, Chemotherapy, Never smoker

The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma

Accumulating evidence reveals the association between the risk of never-smoker lung cancer and family history of cancer. However, the clinicogenomic effect of family history of cancer in never-smoker lung cancer remains unknown.We screened 3,241 lung cancer patients who (a) underwent curative resection at National Cancer Center (Goyang, Korea) between 2001–2014, and (b) completed a pre-designed interview about family/smoking history at the time of diagnosis and identified 604 female never smoker lung adenocarcinoma. A positive family history of cancer [categorized as pulmonary cancer (FH-PC) or non-pulmonary cancer (FH-NPC)] was defined as a self-reported history of cancer in first-degree relatives. Survival data were followed up until January 2017. Multiplexed targeted next-generation sequencing was performed for genetic profiling.The study found that the type of family history of cancer was associated with distinct clinocogenomic subtypes and prognosis of never-smoker lung adenocarcinoma. READ ARTICLE

Lung Cancer DOI:10.1016/j.lungcan.2019.07.031

Authors: Youngjoo Lee, Jae Hyun Jeon, Sung-Ho Goh, Hanseong Roh, Ji-Young Yun, Nak-Jung Kwon, Jin Ho Choi, Hee Chul Yang, Moon Soo Kim, Jong Mog Lee, Geon Kook Lee, Ji-Youn Han

Case StudyKirk SmithJuly 31, 2019Never smoker, Non-small-cell lung cancer, Prognosis, Family history, EGFR, ALK